Taking stock of the drug industry, from the lab to the medicine chestJuly 14, 2023Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Illustration: Alex Hogan/STAT; Photo: Eisai via AP STAT+ | With momentum on Alzheimer's therapies, Europe sees delivery challenges ahead, too Despite hard-won victories, the arrival of new therapies presents new challenges in Europe as countries plan for their possible rollouts. By Andrew Joseph STAT+ | Three women sue cancer diagnostic firm Grail alleging harassment, retaliation In a statement, a spokesman for Grail said the company was reviewing the complaints but was "confident that the claims are without merit." By Matthew Herper STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Kevin Dietsch/AP Democrats press government to extend free Covid-19 tests indefinitely Four senators want the U.S Preventive Services Task Force to act so that insurers must cover the product with no copay for enrollees. By Sarah Owermohle In N.C., Mandy Cohen built bridges to GOP. Can she find consensus as new CDC director? Cohen had a remarkably bipartisan record in a state with a fair share of partisan rancor. But Washington could present new challenges. By Joanne Kenen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments